SAS Output

26-MAY-2017 18:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9138 812 403 219 82 19 BREAST
        9138 812 403 219 82 19  
 
  2 Y 2 Chemo and Endocrine Therapy 2452 274 125 73 27 4  
      3 Endocrine Therapy Alone 2443 275 131 78 28 7  
        4895 549 256 151 55 11  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 618 227 115 63 18 5 BREAST
      2 Blinded drug + Endocrine 612 222 110 60 19 4  
        1230 449 225 123 37 9  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization: Surgery 1 0 0 0 0 0 SURV
      3 Patient Choice: Surgery 25 17 9 5 2 0  
      4 Patient Choice: Non-surgical M 53 33 19 10 2 0  
        79 50 28 15 4 0  
 
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 1 Y 1 Tissue for PD-L1 testing 1150 980 545 279 92 20 MELAN
        1150 980 545 279 92 20  
 
  2 Y 2 FDA approved regimen 525 460 268 130 38 15  
      3 MK-3475 (Pembrolizumab) 518 454 254 132 39 8  
        1043 914 522 262 77 23  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 205 205 193 114 38 10 CCD
      2 Site randomized: Control 75 75 75 64 20 5  
      3 SiteRand Int Risk: CSF 102 102 102 62 23 6  
      4 SiteRand Int Risk: No CSF 66 66 65 50 29 7  
        448 448 435 290 110 28  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 55 55 44 31 14 4 CCD
        55 55 44 31 14 4  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 32 32 32 26 14 4 BREAST
        32 32 32 26 14 4  
 
  2 Y 2 Observation 11 11 11 11 7 4  
      3 MK-3475 (Pembrolizumab) 13 13 13 10 7 2  
        24 24 24 21 14 6  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 4 4 4 4 1 0 GU
      2 Tokyo-172 BCG 2 2 2 2 0 0  
      3 Prime + Tokyo-172 BCG 3 3 3 3 2 1  
        9 9 9 9 3 1  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 353 124 64 26 11 0 PREV
        353 124 64 26 11 0  
 
  1 Y 1 Blinded drug 39 18 9 7 3 0  
      2 Blinded drug 36 12 9 2 0 0  
      3 Blinded drug 35 14 9 3 0 0  
      4 Blinded drug 37 14 10 7 2 0  
        147 58 37 19 5 0